This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Microsoft says Windows 11 multiple rebooting is expected behavior. The problem with Windows ...

Plant owners and operators are always trying to do more with less, but finding solutions to the problems currently impacting manufacturing environments isn’t so simple. The reason is that ...

MELBOURNE, Australia and SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE)-- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

A round-up of upcoming entertainment events, such as concerts, plays, music in the park, author events in the Brainerd lakes area. Casey Hochhalter, Central Lakes College Studio Arts instructor, will ...

Please provide your email address to receive an email when new articles are posted on . The first disease-modifying therapies have transformed the management of geographic atrophy. Patient selection ...

An experimental drug that Theravance Biopharma touted as a potential first-in-class medicine for multiple system atrophy has failed a Phase 3 study, triggering a corporate shakeup that ends this ...

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN ...

HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...

Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study. The Japanese pharma had been evaluating the alpha-synuclein antibody, called ...

Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...